B-100 Complex (vitamin B complex 100 combination no.2)
Multivitamins Oral Tablet, Extended Release
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: This product is a combination of B vitamins used to treat or prevent vitamin deficiency due to poor diet, certain illnesses, alcoholism, or during pregnancy. Vitamins are important building blocks of the body and help keep you in good health. B vitamins include thiamine, riboflavin, niacin/niacinamide, vitamin B6, vitamin B12, folic acid, and pantothenic acid.
Some brands of B vitamins also contain ingredients such as vitamin C, vitamin E, biotin, or zinc. Consult your doctor or pharmacist if you have questions about the ingredients in your brand.
Generic name: vitamin B complex 100 combination no.2
Drug class: Multivitamins
Therapeutic class: Electrolyte Balance-Nutritional Products
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on B-100 Complex
Indications
No indications are available for this drug.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Pyridoxine/Altretamine
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: The mechanism by which pyridoxine adversely affects response duration while coadministering altretamine is not known at this time and requires further investigation.
CLINICAL EFFECTS: The coadministration of oral pyridoxine with chemotherapy regimens consisting of oral altretamine adversely affected response duration.(1,2)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Although pyridoxine administration significantly reduces the neurotoxicity associated with altretamine, it should not be administered with altretamine due to its adverse effect on response duration.(1,2)
DISCUSSION: In a study, 248 patients with Stages III-IV ovarian epithelial cancer were randomized to one of four cisplatin and altretamine regimens. In each regimen, oral altretamine (200 mg/m2 daily) was administered on days 8-21. In addition, intravenous cisplatin was administered on day 1 (37.5 mg/m2, regimens A and B, or 75 mg/m2, regimens C and D). Oral pyridoxine (300 mg/m2 daily, days 1-21) was added to regimens B and D. While pyridoxine did decrease neurologic toxicity and had no effect on response, pyridoxine was found to adversely affect response duration in all patients. This effect was the greatest in previously untreated patients. In addition, pyridoxine had a slight negative effect on failure-free survival in previously untreated patients.(1)
There are no severe interactions for this drug.
Moderate Interaction: Assess the risk to the patient and take action as needed.
Folic Acid/Pafolacianine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Folate, folic acid, and folate-containing supplements may reduce binding of pafolacianine to folate receptors expressed on ovarian cancer cells.
CLINICAL EFFECTS: Folate, folic acid, and folate-containing supplements could reduce the detection of malignant lesions with pafolacianine.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Avoid administration of folate, folic acid, or folate-containing supplements within 48 hours before administration of pafolacianine.
DISCUSSION: Folate, folic acid, and folate-containing supplements may reduce binding of pafolacianine to folate receptors expressed on cancer cells, which could result in reduced detection of malignant lesions with pafolacianine.
Folic Acid; Pyrimethamine/Hydantoins
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Unknown, but probably involves altered metabolism of the hydantoin.
CLINICAL EFFECTS: May observe decreased effectiveness of hydantoin, resulting in loss of seizure control.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: If both drugs are administered, monitor both the hydantoin plasma levels as well as the seizure control of the patient. Adjust the dose of hydantoin accordingly.
DISCUSSION: The effects of an interaction are not expected to occur in the majority of patients. Discontinuation of folic acid has caused phenytoin levels to increase in patients who experienced a decrease in phenytoin levels when folic acid was started. Monitor these patients for hydantoin toxicity. Signs and symptoms of hydantoin toxicity include ataxia, nystagmus and involuntary movements.
Pyridoxine/Levodopa
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Pyridoxine increases levodopa metabolism, decreasing the amount of levodopa available to the central nervous system.
CLINICAL EFFECTS: The pharmacologic effects of levodopa may be decreased.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Avoid pyridoxine in patients receiving levodopa alone; however, the interaction can be minimized by giving levodopa with a peripheral decarboxylase inhibitor (e.g. carbidopa, benserazide). Treatment with combination carbidopa-levodopa may contribute to reduced vitamin B6 levels. Higher doses of carbidopa-levodopa may increase the risk of vitamin B6 deficiency. Seizures associated with vitamin B6 deficiency have been reported in the postmarketing setting. In patients taking combination therapy with carbidopa/levodopa, evaluate vitamin B6 levels periodically while on treatment or if symptoms associated with vitamin B6 deficiency are identified. Supplement with vitamin B6 as necessary.
DISCUSSION: In patients with Parkinson's disease, as little as 10 mg of pyridoxine may reverse the clinical benefits as well as the adverse effects of levodopa. Coadministration of levodopa with either carbidopa or benserazide has minimized the effects of this interaction.
Thiamine/Patiromer
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Patiromer may bind to thiamine.(1)
CLINICAL EFFECTS: Concurrent use may result in decreased gastrointestinal absorption and loss of efficacy of thiamine.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The US manufacturer of patiromer recommends administering patiromer at least 3 hours before or 3 hours after thiamine.(1)
DISCUSSION: An in vitro binding study found potentially clinically significant binding of thiamine by patiromer. It is recommended to take these drugs 3 hours apart.(1)
Contraindications
There is no enhanced messaging for this drug.
- Leber's hereditary optic atrophy
- Systemic mastocytosis
- Atrophic gastritis
- Hypokalemia
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Bronchospastic pulmonary disease
- Concentration difficulty
Rare or Very Rare
- Abdominal distension
- Acute cognitive impairment
- Anorexia
- Depression
- Dysgeusia
- Erythema
- Excitement
- Flatulence
- Irritability
- Malaise
- Nausea
- Pruritus of skin
- Skin rash
- Sleep disorder
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.